Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer

BJU Int. 2020 Oct;126(4):433-435. doi: 10.1111/bju.15151. Epub 2020 Aug 4.

Angelyn Anton¹, Olfat Kamel Hasan^{2

3}, Zita Ballok⁴, Patrick Bowden⁵, Anthony J Costello^{6

7}, Laurence Harewood^{6

8

9}, Niall M Corcoran^{6

7

9}, Phil Dundee^{6

7}, Justin S Peters⁶, Nathan Lawrentschuk^{2

8}, Andrew Troy⁸, David Webb⁸, Yee Chan⁸, Andrew See⁵, Shankar Siva^{2

5}, Declan Murphy^{2

10}, Michael S Hofman^{2

10}, Ben Tran^{1

2

8}

¹ Walter and Eliza Hall Institute, Melbourne, Vic., Australia.
² Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
³ Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
⁴ Healthcare Imaging Services, Melbourne, Vic., Australia.
⁵ ICON Cancer Care, Melbourne, Vic., Australia.
⁶ Royal Melbourne Hospital, Melbourne, Vic., Australia.
⁷ Australian Prostate Centre, Melbourne, Vic., Australia.
⁸ Epworth Healthcare, Melbourne, Vic., Australia.
⁹ Department of Surgery, University of Melbourne, Melbourne, Vic., Australia.
¹⁰ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.

No abstract available

MeSH terms